CFTR and cystic fibrosis: The novel CFTR potentiator ivacaftor (KalydecoTM, VX-770) was recently approved for use in CF patients with the G551D-CFTR gating mutation based on marked improvements in multiple clinical endpoints in phase 2 and 3 trials [15], [16].